Publication: The Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenoma
1
Issued Date
2016-12-01
Resource Type
ISSN
15330346
Other identifier(s)
2-s2.0-84994884825
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Technology in Cancer Research and Treatment. Vol.15, No.6 (2016), NP10-NP15
Suggested Citation
Putipun Puataweepong, Mantana Dhanachai, Ake Hansasuta, Somjai Dangprasert, Thiti Swangsilpa, Chomporn Sitathanee, Chuleeporn Jiarpinitnun, Patamintita Vitoonpanich, Pornpan Yongvithisatid The Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenoma. Technology in Cancer Research and Treatment. Vol.15, No.6 (2016), NP10-NP15. doi:10.1177/1533034615607113 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/42303
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The Clinical Outcome of Hypofractionated Stereotactic Radiotherapy With CyberKnife Robotic Radiosurgery for Perioptic Pituitary Adenoma
Other Contributor(s)
Abstract
© 2015, © The Author(s) 2015. Stereotactic radiation technique including single fraction radiosurgery and conventional fractionated stereotactic radiotherapy is widely reported as an effective treatment of pituitary adenomas. Because of the restricted radiation tolerance dose of the optic pathway, single fraction radiosurgery has been accepted for small tumor located far away from the optic apparatus, while fractionated stereotactic radiotherapy may be suitable for larger tumor located close to the optic pathway. More recently, hypofractionated stereotactic radiotherapy has become an alternative treatment option that provides high rate of tumor control and visual preservation for the perioptic lesions within 2 to 3 mm of the optic pathway. The objective of the study was to analyze the clinical outcomes of perioptic pituitary adenomas treated with hypofractionated stereotactic radiotherapy. From 2009 to 2012, 40 patients with perioptic pituitary adenoma were treated with CyberKnife robotic radiosurgery. The median tumor volume was 3.35 cm3(range, 0.82-25.86 cm3). The median prescribed dose was 25 Gy (range, 20-28 Gy) in 5 fractions (range, 3-5). After the median follow-up time of 38.5 months (range, 14-71 months), 1 (2.5%) patient with prolactinoma had tumor enlargement, 31 (77.5%) were stable, and the remaining 8 (20%) tumors were smaller in size. No patient’s vision deteriorated after hypofractionated stereotactic radiotherapy. Hormone normalization was observed in 7 (54%) of 13 patients. No newly developed hypopituitarism was detected in our study. These data confirmed that hypofractionated stereotactic radiotherapy achieved high rates of tumor control and visual preservation. Because of the shorter duration of treatment, it may be preferable to use hypofractionated stereotactic radiotherapy over fractionated stereotactic radiotherapy for selected pituitary adenomas immediately adjacent to the optic apparatus.